Repligen Corporation
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| RGN.F | SRT3.DE | BLFS | AVTR | DIM.PA | AZTA | |
|---|---|---|---|---|---|---|
| Market cap | 10.03B | 18.17B | — | 11.24B | 20.49B | 1.57B |
| P/E (TTM) | 250.7 | 96.0 | — | — | 70.0 | — |
| Forward P/E | 52.3 | 41.5 | — | 18.9 | 35.0 | 64.7 |
| Price/book | 4.7 | 6.7 | — | 2.0 | 4.8 | 1.0 |
| Dividend yield | — | 0.28% | — | — | 0.33% | — |
| 1-year change | +19.61% | +8.68% | — | +9.63% | +1.32% | +12.68% |
| Today | −1.16% | −0.60% | 0.00% | +2.03% | −2.05% | +2.55% |
The closest companies by business and industry (Medical Instruments & Supplies). Prices may be delayed up to 15 min.
Latest news
All RGN.F news ›Azenta, Myriad Genetics, Moderna, Repligen, and PacBio Shares Plummet, What You Need To Know
A number of stocks fell in the afternoon session after capital-intensive growth equities experienced sharp sell-offs as elevated bond yields restricted market appetite for risk. As reported by CNBC, rising Treasury yields put direct,…
Repligen: A Buy As Its Growth Engine Gears Up
(NASDAQ:RGEN) Seeking Alpha - Repligen demonstrates 13% organic growth despite Filtration headwinds, with strong momentum in the Proteins and Process Analytics segments. - Filtration's drag is temporary, with mid-single-digit growth…
Repligen to Report Third Quarter 2026 Financial Results
GlobeNewswire 13, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), today announced that the Company will report its third quarter 2026 financial results on Tuesday, October 27, 2026 The Company will issue a press release before…
Repligen: Abigail P. Johnson reports 13% stake
One holder reports no voting power in Repligen (RGEN), despite a 7.36M-share passive stake. Stock Titan - [SCHEDULE 13G/A] REPLIGEN CORP Amended Passive Investment Disclosure Repligen: Abigail P. Johnson reports 13% stake FMR reported sole…
Repligen CEO sells 4,202 shares at $190 per share
Repligen Corporation (RGEN) is a global life sciences company in Waltham, MA, focused on bioprocessing technologies for biological drug manufacturing. Repligen CEO sells 4,202 shares at $190 per share Both reported sales were made under a…
Repligen completes BioLife Solutions acquisition
Repligen said BioLife will benefit from its broader global reach, including Asia Pacific, while Repligen will benefit from BioLife’s trusted customer relationships. At closing, shares issuable under BioLife options, RSUs, PSUs and RSAs…
Repligen CEO has 1,248 shares withheld for taxes
Repligen Corporation (RGEN) is a global life sciences company in Waltham, MA, focused on bioprocessing technologies for biological drug manufacturing. Repligen CEO has 1,248 shares withheld for taxes The withholding satisfied tax…
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Most coverage from
-
stocktitan.net7
-
globenewswire.com2
-
news.alphastreet.com1
-
seekingalpha.com1
-
stockstory.org1
Finance and business coverage in the 4Search news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 12 articles, not a forecast.